

Case Report

Ondansetron in a Paxlovid Intolerant Man

Cubeddu LG¹, Dalley TM² and Cubeddu LX^{3*}¹College of Undergraduate Science, Nova SE University, Davie, FL, USA²Department of Emergency Medicine, Mount Sinai Medical Center, Miami Beach, FL, USA³Health Professions Division, Nova SE University, Davie, FL, USA***Corresponding author:** Luigi X Cubeddu, Health Professions Division, Nova SE University, Davie, FL, USA**Received:** July 19, 2022; **Accepted:** August 20, 2022;**Published:** August 27, 2022**Abstract**

A symptomatic 22-year-old man, unvaccinated and living with high-risk elder parents, was prescribed nirmatrelvir/ritonavir (Paxlovid®) after testing positive for COVID-19. The patient developed persistent moderate to severe nausea after the first dose, progressing to severe nausea and several vomiting episodes after the second dose. To avoid discontinuing Paxlovid, a trial with ondansetron 8 mg PO, was initiated, with the first dose given one hour after the last vomiting episode. Due to the improvement in nausea and absence of retching and vomiting, treatment was continued at a dose of 8 mg PO, twice daily, 1-2 hours before each Paxlovid dose, and maintained until completion of the five-day antiviral treatment. No nausea or vomiting was reported during treatment with ondansetron.

In COVID-19 patients intolerant to Paxlovid, due to development of moderate to severe nausea and vomiting, use of ondansetron may prevent treatment discontinuation, and allow completion of the recommended course of therapy. Ondansetron is not expected to exert drug-interactions with the nirmatrelvir-ritonavir combination.

Background

Paxlovid®, is an orally active antiviral combination of nirmatrelvir and ritonavir. Nirmatrelvir, the anti-SARS-COV-2 component, works intracellularly to inhibit the main viral 3CL protease (M^{pro}) interfering with viral replication [1]. Ritonavir prevents nirmatrelvir degradation by Cytochrome 3A4 (1), increasing and sustaining therapeutic nirmatrelvir anti-COVID-19 concentrations [2]. Efficacy and safety of nirmatrelvir-ritonavir combination against COVID-19 has been demonstrated [3-5]. In an outpatient, randomized, placebo-controlled trial, of unvaccinated adults with mild-to-moderate COVID-19, initiation of Paxlovid treatment ≤3 days after onset of symptoms, reduced COVID-related hospitalizations, and all-cause deaths [3]. In December of 2021, the FDA granted an Emergency Use Authorization of Paxlovid for the treatment of non-hospitalized adults and pediatric patients aged ≥12 years and weighing ≥40 kg with mild to moderate COVID-19 who are at high risk of disease progression [4]. Recently, the WHO strongly endorsed Paxlovid use in unvaccinated, older and in immunosuppressed individuals with non-severe COVID-19 [5]. Noserioussafety issues have been reported with the nirmatrelvir-ritonavir combination [3-5]. Mild to moderate dysgeusia, nausea, vomiting, and diarrhea, are the most frequently reported side effects [3-5,7]. Adverse effects can lead to medication non-compliance and premature discontinuation of the recommended 5 day course of therapy. Given its novelty, clinicians prescribing Paxlovid must be familiar with the medication side effect profile and gain experience with treatment modalities which may abate symptoms that lead to treatment non-compliance.

Case Presentation

A 22 years old, white Hispanic male, who two days after contact with a COVID-19 positive person, developed intense chills, fever (average 38.3°C), sore throat, nasal congestion, malaise, tiredness, and generalized muscle aches. Symptoms persisted for 36 hours

which prompted the patient's presentation for evaluation. On physical examination, the patient's initial vital signs included a blood pressure of 128/64, pulse of 105 beats per minute, oral temp of 38.4°C, respiratory rate of 20 breaths per minute and an oxygen saturation of 98% on room air. The patient was overall well appearing and in no acute distress. The patient's neck was supple with no appreciable lymphadenopathy. The cardiac examination was regular rate and rhythm without murmurs, gallops, or rubs. Distal pulses were 2+ in the radial, dorsal is pedis and posterior tibial arteries. The lung examination was clear to auscultation bilaterally. The abdomen was non tender to palpation and there was no rash appreciated on the skin exam.

On the day of presentation, the patient tested positive for COVID-19 by polymerase chain reaction. Patient had a previous PCR confirmed COVID-19 infection in October of 2020 and had received a single dose of the Pfizer-Biontech vaccine in February 2021. Because the case subject is not fully vaccinated, and is currently living with elder, high-risk parents, isolation and Paxlovid treatment were prescribed.

Treatment and Outcome

Paxlovid treatment was started approximately 38 hours after the initiation of symptoms. Approximately two-hours after the first dose, the patient started complaining of severe nausea (VAS: 7/10) [8], food aversion and dysgeusia, which persisted for rest of the dose interval. One hour after the second dose, the intensity of the nausea increased (VAS 10/10), followed by two vomiting episodes. Due to the persistence and exacerbation of the severe nausea and vomiting, the patient requested an alternative treatment to Paxlovid. After discussing pros and cons of treatment discontinuation, a trial with ondansetron, 8 mg PO, was initiated, with the first dose administered one hour after the vomiting episodes. After the first dose of ondansetron, nausea intensity ameliorated (VAS 3/10), and no new

episodes of retching or vomiting were reported. Due to the favorable response, ondansetron, 8 mg PO, was administered twice daily, 1-2 hours before each of Paxlovid doses, and continued until completion of the five-days antiviral treatment. The nausea disappeared after second dose of ondansetron, appetite improved, and no further nausea or vomiting was reported through the rest of the Paxlovid treatment. The taste alteration, although milder, persisted throughout the treatment period. No jaundice, abdominal pain, diarrhea, or any other new symptoms were reported. Finger oximetry SpO₂ averaged 98%. Covid-related symptoms gradually subsided, no chills or fever were present after the fourth day, with residual occasional cough and tiredness at day 8 of symptoms onset. The patient is currently asymptomatic (day 12) and in good health.

Discussion

The efficacy of ondansetron against the nausea and vomiting associated with Paxlovid treatment, may add to the list of off label uses of ondansetron [9]. Ondansetron, a selective 5-HT₃ receptor antagonist, was developed for the prevention and treatment of highly and moderately emetogenic chemotherapeutic regimens [9,10]. These regimens induce massive degranulation of enterochromaffin cells releasing large amounts of serotonin, which acting on 5-HT₃ receptors on enteric vagal afferents, signal the emetic reflex [10]. Ondansetron has also shown antiemetic efficacy for cyclophosphamide-based regimens, and radiation-induced and postoperative nausea and vomiting [9,11]. Off label use ondansetron in acute gastroenteritis, drug overdose, and in pregnancy and hyperemesis gravidarum, has also been reported [9,12,13].

Ritonavir is a potent inhibitor of cytochrome P-450 3A4, increasing the risk of clinically significant drug interactions. Noteworthy, ondansetron can be safely administered combined with nirmatrelvir-ritonavir, because ondansetron is not selectively metabolized, and is neither an inducer nor an inhibitor of cytochrome P-450 3A4 [13]. Ondansetron is metabolized by several of the cytochrome P450 isoforms, CYP1A1, CYP1A2, CYP2D6, and the CYP3A, with no preference for a single form, which minimizes clinically significant interactions. Medications with a narrow margin of safety, and that are metabolized via the cytochrome P450 3A4, such as ranolazine, amiodarone, dronedarone, flecainide, colchicine, lurasidone, clozapine, and midazolam, among others, should be avoided or their dose reduced, if combined with Paxlovid [15,16].

Summary

In summary, we report an additional novel application of ondansetron in a patient with COVID-19 who developed severe nausea and vomiting episodes upon treatment initiation with Paxlovid. Addition of ondansetron allowed completion of the full 5-days treatment with the antiviral combination pills. Although, nausea, may also be a symptom of a COVID-19 infection (16), the observation that the nausea and vomiting developed not before, but promptly after the first dose and intensified promptly after the second dose, suggests that these symptoms were likely induced by the antiviral medication.

Learning Points

- Nirmatrelvir-ritonavir (Paxlovid) is the first oral

medication to receive FDA Emergency Use Authorization (EUA) for the treatment of COVID 19. Mild to moderate dysgeusia, nausea, vomiting, and diarrhea, are the most frequently reported side effects.

- Given its novelty, clinicians prescribing Paxlovid must be familiar with the medication side effect profile and gain experience with treatment modalities which may abate symptoms that lead to treatment non-compliance.

- Ondansetron, a selective 5-HT₃ receptor antagonist, may provide relief of the nausea and vomiting associated with Paxlovid treatment in patients with COVID 19, allowing treatment completion and full anti-COVID efficacy. Ondansetron can be safely administered combined with nirmatrelvir-ritonavir because ondansetron is not selectively metabolized, and is neither an inducer nor an inhibitor of cytochrome P-450 3A4.

Contributors

LGC, MD and LCX contributed equally to the planning, conduct, concept, and authorship of the paper and are requesting to join first authorship.

Funding

No specific grants for this research were requested from any funding agency in the public, commercial or not-for-profit sectors.

References

1. Dafydd R Owen, Charlotte M N Allerton, Annaliesia S Anderson, Lisa Aschenbrenner, Melissa Avery, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. *Science*. 2021; 374: 1586-593.
2. Sevrioukova IF, Poulos TL. Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. *Proceedings of the National Academy of Sciences*. 2010; 107: 18422-18427.
3. Jennifer Hammond, Heidi Leister-Tebbe, Annie Gardner, Paula Abreu, Weihang Bao, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. *N Engl J Med*. 2022; 386: 1397-408.
4. <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19>
5. <https://www.who.int/news/item/22-04-2022-who-recommends-highly-successful-covid-19-therapy-and-calls-for-wide-geographical-distribution-and-transparency-from-originator>
6. <https://www.ema.europa.eu/en/news/ema-issues-advice-use-paxlovid-pf-07321332-ritonavir-treatment-covid-19-rolling-review-starts>
7. <https://www.nhs.uk/medicines/paxlovid/side-effects-of-paxlovid/>
8. Boogaerts JG, Vanacker E, Seidel L, Albert A, Bardiau FM. Assessment of postoperative nausea using a visual analogue scale. *Acta Anaesthesiologica Scandinavica*. 2000; 44: 470-474.
9. Wilde MI, Markham A. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. *Drugs*. 1996; 52: 773-794.
10. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. *The New England journal of medicine*. 1990; 322: 810-816.
11. Cubeddu LX, Pendergrass K, Ryan T, et al. Efficacy of oral ondansetron, a selective antagonist of 5-HT₃ receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group. *Am J Clin Oncol*. 1994; 17: 137-46.
12. Cubeddu LX, Trujillo LM, Talmaciu I, Gonzalez V, Guariguata J, Seijas J, et al. Antiemetic activity of ondansetron in acute gastroenteritis. *Alimentary Pharmacology & Therapeutics*. 1997; 11: 185-191.

13. Parker SE, Van Bennekom C, Anderka M, et al. National Birth Defects Prevention Study. Ondansetron for Treatment of Nausea and Vomiting of Pregnancy and the Risk of Specific Birth Defects. *Obstet Gynecol.* 2018; 13: 385-94.
14. Haan LDD, Mulder PHD, Beex LV, Debruyne FM, Challoner T, Pauw BED. The efficacy of GR38032F, an antagonist of 5-hydroxytryptamine-3 (5-HT₃) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting. *European journal of cancer & clinical oncology.* 1988; 24: 1383-1384.
15. <https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ritonavir-boosted-nirmatrelvir--paxlovid-/paxlovid-drug-drug-interactions/>
16. <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html> 13.